345 related articles for article (PubMed ID: 12079005)
1. Reversal of cannabinoids (delta9-THC) by the benzoflavone moiety from methanol extract of Passiflora incarnata Linneaus in mice: a possible therapy for cannabinoid addiction.
Dhawan K; Kumar S; Sharma A
J Pharm Pharmacol; 2002 Jun; 54(6):875-81. PubMed ID: 12079005
[TBL] [Abstract][Full Text] [Related]
2. Suppression of alcohol-cessation-oriented hyper-anxiety by the benzoflavone moiety of Passiflora incarnata Linneaus in mice.
Dhawan K; Kumar S; Sharma A
J Ethnopharmacol; 2002 Jul; 81(2):239-44. PubMed ID: 12065157
[TBL] [Abstract][Full Text] [Related]
3. Precipitated cannabinoid withdrawal is reversed by Delta(9)-tetrahydrocannabinol or clonidine.
Lichtman AH; Fisher J; Martin BR
Pharmacol Biochem Behav; 2001; 69(1-2):181-8. PubMed ID: 11420084
[TBL] [Abstract][Full Text] [Related]
4. Attenuation of benzodiazepine dependence in mice by a tri-substituted benzoflavone moiety of Passiflora incarnata Linneaus: a non-habit forming anxiolytic.
Dhawan K; Dhawan S; Chhabra S
J Pharm Pharm Sci; 2003; 6(2):215-22. PubMed ID: 12935433
[TBL] [Abstract][Full Text] [Related]
5. Nicotine reversal effects of the benzoflavone moiety from Passiflora incarnata Linneaus in mice.
Dhawan K; Kumar S; Sharma A
Addict Biol; 2002 Oct; 7(4):435-41. PubMed ID: 14578021
[TBL] [Abstract][Full Text] [Related]
6. CB1 receptor antagonist precipitates withdrawal in mice exposed to Delta9-tetrahydrocannabinol.
Cook SA; Lowe JA; Martin BR
J Pharmacol Exp Ther; 1998 Jun; 285(3):1150-6. PubMed ID: 9618417
[TBL] [Abstract][Full Text] [Related]
7. Discriminative stimulus effects of the cannabinoid CB1 antagonist SR 141716A in rhesus monkeys pretreated with Delta9-tetrahydrocannabinol.
McMahon LR
Psychopharmacology (Berl); 2006 Oct; 188(3):306-14. PubMed ID: 16953389
[TBL] [Abstract][Full Text] [Related]
8. Restoration of chronic-Delta 9-THC-induced decline in sexuality in male rats by a novel benzoflavone moiety from Passiflora incarnata Linn.
Dhawan K; Sharma A
Br J Pharmacol; 2003 Jan; 138(1):117-20. PubMed ID: 12522080
[TBL] [Abstract][Full Text] [Related]
9. Reversal of SR 141716A-induced head-twitch and ear-scratch responses in mice by delta 9-THC and other cannabinoids.
Janoyan JJ; Crim JL; Darmani NA
Pharmacol Biochem Behav; 2002; 71(1-2):155-62. PubMed ID: 11812518
[TBL] [Abstract][Full Text] [Related]
10. Opioid and cannabinoid modulation of precipitated withdrawal in delta(9)-tetrahydrocannabinol and morphine-dependent mice.
Lichtman AH; Sheikh SM; Loh HH; Martin BR
J Pharmacol Exp Ther; 2001 Sep; 298(3):1007-14. PubMed ID: 11504797
[TBL] [Abstract][Full Text] [Related]
11. Dependence of mesolimbic dopamine transmission on delta9-tetrahydrocannabinol.
Tanda G; Loddo P; Di Chiara G
Eur J Pharmacol; 1999 Jul; 376(1-2):23-6. PubMed ID: 10440085
[TBL] [Abstract][Full Text] [Related]
12. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys.
Nakamura-Palacios EM; Winsauer PJ; Moerschbaecher JM
Behav Pharmacol; 2000 Aug; 11(5):377-86. PubMed ID: 11103889
[TBL] [Abstract][Full Text] [Related]
13. Drug/substance reversal effects of a novel tri-substituted benzoflavone moiety (BZF) isolated from Passiflora incarnata Linn.--a brief perspective.
Dhawan K
Addict Biol; 2003 Dec; 8(4):379-86. PubMed ID: 14690874
[TBL] [Abstract][Full Text] [Related]
14. Comparative anxiolytic activity profile of various preparations of Passiflora incarnata linneaus: a comment on medicinal plants' standardization.
Dhawan K; Kumar S; Sharma A
J Altern Complement Med; 2002 Jun; 8(3):283-91. PubMed ID: 12165186
[TBL] [Abstract][Full Text] [Related]
15. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.
Huang P; Liu-Chen LY; Unterwald EM; Cowan A
Neurosci Lett; 2009 Nov; 465(1):66-70. PubMed ID: 19733208
[TBL] [Abstract][Full Text] [Related]
16. Delta9-THC induced hyperphagia and tolerance assessment: interactions between the CB1 receptor agonist delta9-THC and the CB1 receptor antagonist SR-141716 (rimonabant) in rats.
Järbe TU; DiPatrizio NV
Behav Pharmacol; 2005 Sep; 16(5-6):373-80. PubMed ID: 16148441
[TBL] [Abstract][Full Text] [Related]
17. Tolerance and dependence to Δ9-tetrahydrocannabinol in rhesus monkeys: Activity assessments.
Wilkerson JL; Schulze DR; McMahon LR
PLoS One; 2019; 14(3):e0209947. PubMed ID: 30861005
[TBL] [Abstract][Full Text] [Related]
18. Effects of SR 141716A after acute or chronic cannabinoid administration in dogs.
Lichtman AH; Wiley JL; LaVecchia KL; Neviaser ST; Arthur DB; Wilson DM; Martin BR
Eur J Pharmacol; 1998 Sep; 357(2-3):139-48. PubMed ID: 9797029
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of hippocampal acetylcholine release after acute and repeated Delta9-tetrahydrocannabinol in rats.
Carta G; Nava F; Gessa GL
Brain Res; 1998 Oct; 809(1):1-4. PubMed ID: 9795096
[TBL] [Abstract][Full Text] [Related]
20. Rimonabant-induced Delta9-tetrahydrocannabinol withdrawal in rhesus monkeys: discriminative stimulus effects and other withdrawal signs.
Stewart JL; McMahon LR
J Pharmacol Exp Ther; 2010 Jul; 334(1):347-56. PubMed ID: 20375197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
